Agomab Therapeutics NV
AGMBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for AGMB. That does not mean none is planned.
Get an email about AGMB's next catalysts
Track Agomab Therapeutics (AGMB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 0 past
No catalysts found.
Market Overview
Stock performance and key metrics
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
AGMB-129 | Phase 2 | Fibrostenotic Crohn's Disease | - | - |
Ontunisertib | Phase 2 | Fibrostenotic Crohn's Disease | - | - |
Frequently asked questions
What is in Agomab Therapeutics NV's drug pipeline?→
CatalystAlert tracks 2 drug candidates in Agomab Therapeutics NV's (AGMB) pipeline across Phase 2. Its lead program is AGMB-129 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Agomab Therapeutics NV's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Agomab Therapeutics NV (AGMB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AGMB biotech catalysts?→
Add AGMB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Agomab Therapeutics NV's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.